Nymox studies fail
November 03, 2014 at 12:11 PM EST
Nymox Pharmaceutical Corp. (Nasdaq: NYMX) reported disappointing results from two Phase 3 studies of NX-1207. Shares of the biopharmaceutical collapsed $4.22 to $0.92.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.